The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials

Clin Exp Rheumatol. Jul-Aug 2013;31(4 Suppl 78):S19-21. Epub 2013 Oct 3.

Abstract

There has been great interest lately concerning the possibility that in the treatment of rheumatoid arthritis, biologic agents might be withdrawn for patients who achieve desirable targets, such as low disease activity or remission. While there are a number of reasons why such a treatment paradigm might be desirable, there is a paucity of relevant data at present to guide clinicians about embarking on such a treatment change. Data is starting to emerge, much of it from controlled trials, that can provide some guidance as to which patients might be the best candidates for such an approach. These data will provide answers to the key questions that remain concerning this important potential paradigm shift in the treatment of rheumatoid arthritis as well as other systemic inflammatory autoimmune diseases.

MeSH terms

  • Antirheumatic Agents / administration & dosage*
  • Antirheumatic Agents / adverse effects
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Biological Products / administration & dosage*
  • Biological Products / adverse effects
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Evidence-Based Medicine
  • Humans
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic / methods*
  • Recurrence
  • Remission Induction
  • Research Design*
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Biological Products